Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab
Background: There is a lack of surrogate markers to predict the outcomes of nivolumab plus ipilimumab (Nivo-Ipi) for advanced renal cell carcinoma (RCC), but neutrophil to lymphocyte ratio (NLR) and tumour burden are promising candidates. This study investigated biological and radiological surrogate...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | ESMO Real World Data and Digital Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949820124000845 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849711949291454464 |
|---|---|
| author | M. Oshima S. Washino S. Shirotake H. Takeshita M. Inoue Y. Miura A. Nakayama S. Nagamoto T. Nakayama K. Izumi M. Oyama S. Kawakami K. Saito Y. Matsuoka T. Miyagawa |
| author_facet | M. Oshima S. Washino S. Shirotake H. Takeshita M. Inoue Y. Miura A. Nakayama S. Nagamoto T. Nakayama K. Izumi M. Oyama S. Kawakami K. Saito Y. Matsuoka T. Miyagawa |
| author_sort | M. Oshima |
| collection | DOAJ |
| description | Background: There is a lack of surrogate markers to predict the outcomes of nivolumab plus ipilimumab (Nivo-Ipi) for advanced renal cell carcinoma (RCC), but neutrophil to lymphocyte ratio (NLR) and tumour burden are promising candidates. This study investigated biological and radiological surrogate markers in advanced RCC patients receiving Nivo-Ipi. Materials and methods: Between 2018 and 2022, data were retrospectively collected for patients receiving Nivo-Ipi for previously untreated metastatic or locally advanced RCC with intermediate or poor risk across six centres. We assessed prognostic factors to stratify the outcomes of Nivo-Ipi, including tumour burden and NLR. Results: The study included 129 patients with a median age of 67 years (71% men). Both NLR and tumour burden were negatively associated with tumour response; they were also independently associated with unfavourable overall survival, whereas NLR was the only factor independently associated with unfavourable progression-free survival on multivariate analysis. Combined NLR and tumour burden assessment enabled stratification of the outcomes of Nivo-Ipi. Patients with NLR <3.0 or 3.0-5.9 and tumour burden <200 mm showed significantly superior treatment outcomes relative to the other patients with NLR ≥6.0 or 3.0-5.9 and tumour burden ≥200 mm (objective response rate: 54% versus 26%; complete response rate: 16% versus 0%; median overall survival: 44.3 versus 6.1 months; median progression-free survival: 17.4 versus 4.1 months). Conclusions: NLR and tumour burden were negatively associated with response to Nivo-Ipi in advanced RCC. Combined NLR and tumour burden assessment could efficiently stratify treatment outcomes and survival, potentially aiding treatment selection. |
| format | Article |
| id | doaj-art-486d7104a3dd4cadb0ca97ddc1fea196 |
| institution | DOAJ |
| issn | 2949-8201 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | ESMO Real World Data and Digital Oncology |
| spelling | doaj-art-486d7104a3dd4cadb0ca97ddc1fea1962025-08-20T03:14:28ZengElsevierESMO Real World Data and Digital Oncology2949-82012025-03-01710010610.1016/j.esmorw.2024.100106Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumabM. Oshima0S. Washino1S. Shirotake2H. Takeshita3M. Inoue4Y. Miura5A. Nakayama6S. Nagamoto7T. Nakayama8K. Izumi9M. Oyama10S. Kawakami11K. Saito12Y. Matsuoka13T. Miyagawa14Department of Urology, Jichi Medical University Saitama Medical Center, Saitama, Japan; Musashino Study Group, Saitama, JapanDepartment of Urology, Jichi Medical University Saitama Medical Center, Saitama, Japan; Musashino Study Group, Saitama, Japan; Correspondence to: Dr Satoshi Washino, Jichi Medical University Saitama Medical Center, 1-847, Amanuma-cho, Omiya-ku, Saitama, Saitama, 330-8503, Japan. Tel: +81486472111Musashino Study Group, Saitama, Japan; Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, JapanMusashino Study Group, Saitama, Japan; Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, JapanMusashino Study Group, Saitama, Japan; Department of Urology, Saitama Cancer Center, Saitama, JapanMusashino Study Group, Saitama, Japan; Department of Medical Oncology, Toranomon Hospital, Tokyo, JapanMusashino Study Group, Saitama, Japan; Department of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, JapanMusashino Study Group, Saitama, Japan; Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, JapanMusashino Study Group, Saitama, Japan; Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, JapanMusashino Study Group, Saitama, Japan; Department of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, JapanDepartment of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, JapanDepartment of Urology, Saitama Medical Center, Saitama Medical University, Saitama, JapanDepartment of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, JapanDepartment of Urology, Saitama Cancer Center, Saitama, JapanDepartment of Urology, Jichi Medical University Saitama Medical Center, Saitama, JapanBackground: There is a lack of surrogate markers to predict the outcomes of nivolumab plus ipilimumab (Nivo-Ipi) for advanced renal cell carcinoma (RCC), but neutrophil to lymphocyte ratio (NLR) and tumour burden are promising candidates. This study investigated biological and radiological surrogate markers in advanced RCC patients receiving Nivo-Ipi. Materials and methods: Between 2018 and 2022, data were retrospectively collected for patients receiving Nivo-Ipi for previously untreated metastatic or locally advanced RCC with intermediate or poor risk across six centres. We assessed prognostic factors to stratify the outcomes of Nivo-Ipi, including tumour burden and NLR. Results: The study included 129 patients with a median age of 67 years (71% men). Both NLR and tumour burden were negatively associated with tumour response; they were also independently associated with unfavourable overall survival, whereas NLR was the only factor independently associated with unfavourable progression-free survival on multivariate analysis. Combined NLR and tumour burden assessment enabled stratification of the outcomes of Nivo-Ipi. Patients with NLR <3.0 or 3.0-5.9 and tumour burden <200 mm showed significantly superior treatment outcomes relative to the other patients with NLR ≥6.0 or 3.0-5.9 and tumour burden ≥200 mm (objective response rate: 54% versus 26%; complete response rate: 16% versus 0%; median overall survival: 44.3 versus 6.1 months; median progression-free survival: 17.4 versus 4.1 months). Conclusions: NLR and tumour burden were negatively associated with response to Nivo-Ipi in advanced RCC. Combined NLR and tumour burden assessment could efficiently stratify treatment outcomes and survival, potentially aiding treatment selection.http://www.sciencedirect.com/science/article/pii/S2949820124000845neutrophil to lymphocyte ratiotumour burdenrenal cell carcinomanivolumabipilimumab |
| spellingShingle | M. Oshima S. Washino S. Shirotake H. Takeshita M. Inoue Y. Miura A. Nakayama S. Nagamoto T. Nakayama K. Izumi M. Oyama S. Kawakami K. Saito Y. Matsuoka T. Miyagawa Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab ESMO Real World Data and Digital Oncology neutrophil to lymphocyte ratio tumour burden renal cell carcinoma nivolumab ipilimumab |
| title | Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab |
| title_full | Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab |
| title_fullStr | Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab |
| title_full_unstemmed | Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab |
| title_short | Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab |
| title_sort | neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab |
| topic | neutrophil to lymphocyte ratio tumour burden renal cell carcinoma nivolumab ipilimumab |
| url | http://www.sciencedirect.com/science/article/pii/S2949820124000845 |
| work_keys_str_mv | AT moshima neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT swashino neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT sshirotake neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT htakeshita neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT minoue neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT ymiura neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT anakayama neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT snagamoto neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT tnakayama neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT kizumi neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT moyama neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT skawakami neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT ksaito neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT ymatsuoka neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab AT tmiyagawa neutrophiltolymphocyteratioandtumourburdenfortreatmentefficacystratificationinrenalcellcarcinomapatientsreceivingnivolumabplusipilimumab |